| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 42, 1943-1948, Copyright © 1996 by American Association for Clinical Chemistry
KL Napoli and BD Kahan
Department of Surgery, University of Texas Houston Health Science Center-Medical School 77030, USA. knapoli@orgtx71.med.uth.tmc.edu
During phase I/II clinical trials of sirolimus (rapamycin; SRL), therapeutic drug monitoring was performed with a multistep liquid- liquid extraction of 1-mL aliquots of whole blood followed by reversed- phase HPLC with ultraviolet detection. Blood was sampled according to a standardized protocol and clinical status. SRL concentrations were interpolated from calibration curves with a linear range of 0-50 micrograms/L and 1 microgram/L lower limit of quantification. Quality control was monitored over 68 consecutive analytical runs by using frozen aliquots of SRL-supplemented pooled whole blood at 4, 12, and 32 micrograms/L. These samples showed mean concentrations of 3.7 +/- 0.6, 10.9 +/- 1.1, and 29.6 +/- 2.6 micrograms/L, respectively. This method for therapeutic drug monitoring of SRL permits one full-time technician to analyze 100 clinical specimens per week with a 24-h turnaround time. With this method, a strong linear relation (r2 = 0.946, Sy/x = 0.41, n = 115) between the average SRL concentration over a 24-h period and the SRL concentration at the 24th h was revealed.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  G. Khoschsorur Simultaneous Measurement of Sirolimus and Everolimus in Whole Blood by HPLC with Ultraviolet Detection Clin. Chem., September 1, 2005; 51(9): 1721 - 1724. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Annesley and L. Clayton Simple Extraction Protocol for Analysis of Immunosuppressant Drugs in Whole Blood Clin. Chem., October 1, 2004; 50(10): 1845 - 1848. [Full Text] [PDF]
|
|
|
|
|
|
D. C. French, M. Saltzgueber, D. R. Hicks, A. L. Cowper, and D. W. Holt HPLC Assay with Ultraviolet Detection for Therapeutic Drug Monitoring of Sirolimus Clin. Chem., July 1, 2001; 47(7): 1316 - 1319. [Full Text] [PDF]
|
|
|
|
 |
|
 H. PODDER, S. M. STEPKOWSKI, K. L. NAPOLI, J. CLARK, R. R. VERANI, T.-C. CHOU, and B. D. KAHAN Pharmacokinetic Interactions Augment Toxicities of Sirolimus/Cyclosporine Combinations J. Am. Soc. Nephrol., May 1, 2001; 12(5): 1059 - 1071. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. Holt, T. Lee, K. Jones, and A. Johnston Validation of an Assay for Routine Monitoring of Sirolimus Using HPLC with Mass Spectrometric Detection Clin. Chem., August 1, 2000; 46(8): 1179 - 1183. [Full Text] [PDF]
|
|
|
|
|
|
P. Salm, P. J. Taylor, and P. I. Pillans Analytical Performance of Microparticle Enzyme Immunoassay and HPLC-Tandem Mass Spectrometry in the Determination of Sirolimus in Whole Blood Clin. Chem., December 1, 1999; 45(12): 2278 - 2280. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
